Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure inhibit prostate tumor growth in TRAMP mice
Status PubMed-not-MEDLINE Language English Country United States Media electronic-ecollection
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
29209567
PubMed Central
PMC5706615
DOI
10.1080/2162402x.2017.1362528
PII: 1362528
Knihovny.cz E-resources
- Keywords
- dendritic cells, docetaxel, high hydrostatic pressure, immunotherapy, prostate cancer,
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Dendritic cell (DC)-based vaccines pulsed with high hydrostatic pressure (HHP)-inactivated tumor cells have recently been shown to be a promising tool for prostate cancer chemoimmunotherapy. In this study, DC-based vaccines, both pulsed and unpulsed, were as effective as docetaxel (DTX) in reducing prostate tumors in the orthotopic transgenic adenocarcinoma of the mouse prostate (TRAMP) model. However, we did not observe any additive or synergic effects of chemoimmunotherapy on the tumor growth, while only the combination of DTX and pulsed dendritic cells resulted in significantly lower proliferation detected by Ki67 staining in histological samples. The DC-based vaccine pulsed with HHP-treated tumor cells was also combined with another type of cytostatic, cyclophosphamide, with similar results. In another clinically relevant setting, minimal residual tumor disease after surgery, administration of DC-based vaccines after the surgery of poorly immunogenic transplanted TRAMP-C2, as well as in immunogenic TC-1 tumors, reduced the growth of tumor recurrences. To identify the effector cell populations after DC vaccine application, mice were twice immunized with both pulsed and unpulsed DC vaccine, and the cytotoxicity of the spleen cells populations was tested. The effector cell subpopulations were defined as CD4+ and NK1.1+, which suggests rather unspecific therapeutic effects of the DC-based vaccines in our settings. Taken together, our data demonstrate that DC-based vaccines represent a rational tool for the treatment of human prostate cancer.
See more in PubMed
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7-30. doi:10.3322/caac.21387. PMID:28055103 PubMed DOI
Beltran H, Beer TM, Carducci MA, de Bono J, Gleave M, Hussain M, Kelly WK, Saad F, Sternberg C, Tagawa ST, et al.. New therapies for castration-resistant prostate cancer: Efficacy and safety. Eur Urol. 2011;60:279-90. doi:10.1016/j.eururo.2011.04.038. PMID:21592649 PubMed DOI
Maluf FC, Smaletz O, Herchenhorn D. Castration-resistant prostate cancer: Systemic therapy in 2012. Clinics (Sao Paulo, Brazil). 2012;67:389-94. doi:10.6061/clinics/2012(04)13. PMID:22522765 PubMed DOI PMC
Kodumudi KN, Woan K, Gilvary DL, Sahakian E, Wei S, Djeu JY. A novel chemoimmunomodulating property of docetaxel: Suppression of myeloid-derived suppressor cells in tumor bearers. Clin Cancer Res. 2010;16:4583-94. doi:10.1158/1078-0432.CCR-10-0733. PMID:20702612 PubMed DOI PMC
Chen G, Emens LA. Chemoimmunotherapy: Reengineering tumor immunity. Cancer Immunol Immunother. 2013;62:203-16. doi:10.1007/s00262-012-1388-0. PMID:23389507 PubMed DOI PMC
Kirkwood JM, Butterfield LH, Tarhini AA, Zarour H, Kalinski P, Ferrone S. Immunotherapy of cancer in 2012. CA Cancer J Clin. 2012;62:309-35. doi:10.3322/caac.20132. PMID:22576456 PubMed DOI PMC
Emens LA. Chemoimmunotherapy. Cancer J (Sudbury, Mass). 2010;16:295-303. doi:10.1097/PPO.0b013e3181eb5066. PMID:20693839 PubMed DOI PMC
Ramakrishnan R, Antonia S, Gabrilovich DI. Combined modality immunotherapy and chemotherapy: A new perspective. Cancer Immunol Immunother. 2008;57:1523-9. doi:10.1007/s00262-008-0531-4. PMID:18488219 PubMed DOI PMC
Nowak AK, Lake RA, Robinson BW. Combined chemoimmunotherapy of solid tumours: Improving vaccines? Adv Drug Deliv Rev. 2006;58:975-90. doi:10.1016/j.addr.2006.04.002. PMID:17005292 PubMed DOI
Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245-52. doi:10.1038/32588. PMID:9521319 PubMed DOI
Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012;12:265-77. doi:10.1038/nrc3258. PMID:22437871 PubMed DOI PMC
Galluzzi L, Senovilla L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G. Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology. 2012;1:1111-34. doi:10.4161/onci.21494. PMID:23170259 PubMed DOI PMC
Podrazil M, Horvath R, Becht E, Rozkova D, Bilkova P, Sochorova K, Hromadkova H, Kayserova J, Vavrova K, Lastovicka J, et al.. Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer. Oncotarget 2015;6:18192-205. doi:10.18632/oncotarget.4145. PMID:26078335 PubMed DOI PMC
Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, et al.. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411-22. doi:10.1056/NEJMoa1001294. PMID:20818862 PubMed DOI
Vandenberk L, Belmans J, Van Woensel M, Riva M, Van Gool SW. Exploiting the immunogenic potential of cancer cells for improved dendritic cell vaccines. Front Immunol. 2015;6:663. PMID:26834740 PubMed PMC
Adkins I, Fucikova J, Garg AD, Agostinis P, Spisek R. Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy. Oncoimmunology. 2014;3:e968434. doi:10.4161/21624011.2014.968434. PMID:25964865 PubMed DOI PMC
Fucikova J, Moserova I, Truxova I, Hermanova I, Vancurova I, Partlova S, Fialova A, Sojka L, Cartron PF, Houska M, et al.. High hydrostatic pressure induces immunogenic cell death in human tumor cells. Int J Cancer. 2014;135:1165-77. doi:10.1002/ijc.28766. PMID:24500981 PubMed DOI
Mikyskova R, Stepanek I, Indrova M, Bieblova J, Simova J, Truxova I, Moserová I, Fučíková J, Bartůňková J, Špíšek R, et al.. Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure induce strong immune responses and display therapeutic effects both in murine TC-1 and TRAMP-C2 tumors when combined with docetaxel chemotherapy. Int J Oncol. 2016;48:953-64. PMID:26718011 PubMed PMC
Gingrich JR, Barrios RJ, Foster BA, Greenberg NM. Pathologic progression of autochthonous prostate cancer in the TRAMP model. Prostate Cancer Prostatic Dis. 1999;2:70-5. doi:10.1038/sj.pcan.4500296. PMID:12496841 PubMed DOI
Mikyskova R, Indrova M, Simova J, Jandlova T, Bieblova J, Jinoch P, Bubeník J, Vonka V. Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: Cytokine and gene therapy with IL-2 and GM-CSF. Int J Oncol. 2004;24:161-7. PMID:14654953 PubMed
Indrova M, Mikyskova R, Jandlova T, Vonka V, Bubenik J, Bieblova J. Adjuvant cytokine treatment of minimal residual disease after surgical therapy in mice carrying HPV16-associated tumours: Cytolytic activity of spleen cells from tumour regressors. Folia Biol (Praha). 2003;49:217-22. PMID:14748435 PubMed
Bubenik J, Mikyskova R, Vonka V, Mendoza L, Simova J, Smahel M, Indrová M. Interleukin-2 and dendritic cells as adjuvants for surgical therapy of tumours associated with human papillomavirus type 16. Vaccine. 2003;21:891-6. doi:10.1016/S0264-410X(02)00537-6. PMID:12547599 PubMed DOI
Reinis M, Indrova M, Mendoza L, Mikyskova R, Bieblova J, Bubenik J, Símová J. HPV16-associated tumours: Therapy of surgical minimal residual disease with dendritic cell-based vaccines. Int J Oncol. 2004;25:1165-70. PMID:15375569 PubMed
Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, Pardoll DM, Wu TC. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 1996;56:21-6. PMID:8548765 PubMed
Foster BA, Gingrich JR, Kwon ED, Madias C, Greenberg NM. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res. 1997;57:3325-30. PMID:9269988 PubMed
Lutz MB, Kukutsch N, Ogilvie AL, Rossner S, Koch F, Romani N, Schuler G. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods. 1999;223:77-92. doi:10.1016/S0022-1759(98)00204-X. PMID:10037236 PubMed DOI
Indrova M, Reinis M, Bubenik J, Jandlova T, Bieblova J, Vonka V, Velek J. Immunogenicity of dendritic cell-based HPV16 E6/E7 peptide vaccines: CTL activation and protective effects. Folia Biol (Praha). 2004;50:184-93. PMID:15709713 PubMed
Stepanek I, Indrova M, Bieblova J, Fucikova J, Spisek R, Bubenik J, Reinis M. Effects of 5-azacytidine and trichostatin A on dendritic cell maturation. J Biol Regul Homeost Agents. 2011;25:517-29. PMID:22217985 PubMed
Yi AK, Krieg AM. CpG DNA rescue from anti-IgM-induced WEHI-231 B lymphoma apoptosis via modulation of I kappa B alpha and I kappa B beta and sustained activation of nuclear factor-kappa B/c-Rel. J Immunol. 1998;160:1240-5. PMID:9570540 PubMed
Vlk V, Rossner P, Indrova M, Bubenik J, Sobota V. Interleukin-2 gene therapy of surgical minimal residual tumour disease. Int J Cancer. 1998;76:115-9. doi:10.1002/(SICI)1097-0215(19980330)76:1<115::AID-IJC18>3.0.CO;2-B. PMID:9533770 PubMed DOI
Bubenik J, Zeuthen J, Indrova M, Bubenikova D, Simova J. Kinetics and function of peritoneal-exudate cells during local IL-2 gene-therapy of cancer. Int J Oncol. 1994;4:13-6. PMID:21566882 PubMed
Mikyskova R, Indrova M, Pollakova V, Bieblova J, Simova J, Reinis M. Cyclophosphamide-induced myeloid-derived suppressor cell population is immunosuppressive but not identical to myeloid-derived suppressor cells induced by growing TC-1 tumors. J Immunother. 2012;35:374-84. doi:10.1097/CJI.0b013e318255585a. PMID:22576342 PubMed DOI
Mikyskova R, Indrova M, Vlkova V, Bieblova J, Simova J, Parackova Z, Pajtasz-Piasecka E, Rossowska J, Reiniš M. DNA demethylating agent 5-azacytidine inhibits myeloid-derived suppressor cells induced by tumor growth and cyclophosphamide treatment. J Leukoc Biol. 2014;95:743-53. doi:10.1189/jlb.0813435. PMID:24389335 PubMed DOI
Ricupito A, Grioni M, Calcinotto A, Hess Michelini R, Longhi R, Mondino A, Bellone M. Booster vaccinations against cancer are critical in prophylactic but detrimental in therapeutic settings. Cancer Res. 2013;73:3545-54. doi:10.1158/0008-5472.CAN-12-2449. PMID:23539449 PubMed DOI
Chin AI, Miyahira AK, Covarrubias A, Teague J, Guo BC, Dempsey PW, Cheng G. Toll-like Receptor 3-mediated suppression of TRAMP prostate cancer shows the critical role of type I interferons in tumor immune surveillance. Cancer Res. 2010;70:2595-603. doi:10.1158/0008-5472.CAN-09-1162. PMID:20233880 PubMed DOI PMC
Lion E, Smits ELJM, Berneman ZN, Van Tendeloo VFI. NK Cells: Key to success of DC-based cancer vaccines? Oncologist. 2012;17:1256-70. doi:10.1634/theoncologist.2011-0122. PMID:22907975 PubMed DOI PMC
Shimizu K, Fujii SI. DC therapy induces long-term NK reactivity to tumors via host DC. Eur J Immunol. 2009;39:457-68. doi:10.1002/eji.200838794. PMID:19180466 PubMed DOI
Bonaccorsi I, Pezzino G, Morandi B, Ferlazzo G. Novel perspectives on dendritic cell-based immunotherapy of cancer. Immunol Lett. 2013;155:6-10. doi:10.1016/j.imlet.2013.09.021. PMID:24076312 PubMed DOI
Mendoza L, Indrova M, Hajkova R, Reinis M, Smahel M, Vonka V, Bubeník J, Jandlová T. Peritumoral administration of antigen-unstimulated bone marrow-derived dendritic cells inhibits tumour growth. Folia Biol-Prague. 2000;46:91-7. PubMed
Reinis M, Stepanek I, Simova J, Bieblova J, Pribylova H, Indrova M, Bubenik J. Induction of protective immunity against MHC class I-deficient, HPV16-associated tumours with peptide and dendritic cell-based vaccines. Int J Oncol. 2010;36:545-51. doi:10.3892/ijo_00000528. PMID:20126973 PubMed DOI
De Vleeschouwer S, Fieuws S, Rutkowski S, Van Calenbergh F, Van Loon J, Goffin J, Sciot R, Wilms G, Demaerel P, Warmuth-Metz M, et al.. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res. 2008;14:3098-104. doi:10.1158/1078-0432.CCR-07-4875. PMID:18483377 PubMed DOI
